The Hyplip2 locus causes hypertriglyceridemia by decreased clearance of triglycerides

Journal of Lipid Research

Volumn 48, Issue 10, 2007, Pages 2182-2192

  Moen, Corina J A ^a   Tholens, Aart P ^a   Voshol, Peter J ^a,b   De Haan, Willeke ^a   Havekes, Louis M ^a,b   Gargalovic, Peter ^c   Lusis, Aldons J ^c   Van Dyk, Ko Willems ^a   Frants, Rune R ^a   Hofker, Marten H ^d,e   Rensen, Patrick C N ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Congenic mice; Lipoprotein clearance; Lipoprotein lipase; Lipoproteins; Triglyceride hydrolysis

Indexed keywords

CHYLOMICRON; FATTY ACID; LIPOPROTEIN LIPASE; OLIVE OIL; TRIACYLGLYCEROL; TRIOLEIN; TYLOXAPOL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 15; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GENE LOCUS; HYPERTRIGLYCERIDEMIA; HYPLIP2 GENE; INTESTINE ABSORPTION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER; MOUSE; MUTATOR GENE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WHITE ADIPOSE TISSUE;

ANIMALS; CHYLOMICRONS; FEMALE; GENETIC TECHNIQUES; HYPERTRIGLYCERIDEMIA; LIPASE; LIPOPROTEIN LIPASE; LIPOPROTEINS; LIPOPROTEINS, VLDL; MICE; MICE, CONGENIC; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 34948827079     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700009-JLR200     Document Type: Article

References (42)

1. Purcell-Huynh, D. A., A. Weinreb, L. W. Castellani, M. Mehrabian, M. H. Doolittle, and A. J. Lusis. 1995. Genetic factors in lipoprotein metabolism. Analysis of a genetic cross between inbred mouse strains NZB/BINJ and SM/J using a complete linkage map approach. J. Clin. Invest. 96: 1845-1858.
2. Gu, L., M. W. Johnson, and A. J. Lusis. 1999. Quantitative trait locus analysis of plasma lipoprotein levels in an autoimmune mouse model: interactions between lipoprotein metabolism, autoimmune disease, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 19: 442-453.
3. Ishimori, N., R. Li, P. M. Kelmenson, R. Korstanje, K. A. Walsh, G. A. Churchill, K. Forsman-Semb, and B. Paigen. 2004. Quantitative trait loci that determine plasma lipids and obesity in C57BL/6J and 129S1/SvImJ inbred mice. J. Lipid Res. 45: 1624-1632.
4. Lyons, M. A., H. Wittenburg, R. Li, K. A. Walsh, R. Korstanje, G. A. Churchill, M. C. Carey, and B. Paigen. 2004. Quantitative trait loci that determine lipoprotein cholesterol levels in an intercross of 129S1/SvImJ and CAST/Ei inbred mice. Physiol. Genomics. 17: 60-68.
5. Wittenburg, H., M. A. Lyons, R. Li, U. Kurtz, S. Wang, J. Mössner, G. A. Churchill, M. C. Carey, and B. Paigen. 2006. QTL mapping for genetic determinants of lipoprotein cholesterol levels in combined crosses of inbred mouse strains. J. Lipid Res. 47: 1780-1790.
6. Wang, X., P. Gargalovic, J. Wong, J. L. Gu, X. Wu, H. Qi, P. Wen, L. Xi, B. Tan, R. Gogliotti, et al. 2004. Hyplip2, a new gene for combined hyperlipidemia and increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24: 1928-1934.
7. Zambon, A., S. I. Hashimoto, and J. D. Brunzell. 1993. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J. Lipid Res. 34: 1021-1028.
8. Jong, M. C., V. E. Dahlmans, P. J. van Gorp, M. L. Breuer, M. J. Mol, A. van der Zee, R. R. Frants, M. H. Hofker, and L. M. Havekes. 1996. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler. Thromb. Vasc. Biol. 16: 934-940.
9. Redgrave, T. G., D. C. Roberts, and C. E. West. 1975. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 65: 42-49.
10. Yamada, N., and R. J. Havel. 1986. Measurement of apolipoprotein B radioactivity in whole blood plasma by precipitation with isopropanol. J. Lipid Res. 27: 910-912.
11. Borensztajn, J., M. S. Rone, and T. J. Kotlar. 1976. The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by Triton WR-1339. Biochem. J. 156: 539-543.
12. Rensen, P. C., N. Herijgers, M. H. Netscher, S. C. Meskers, M. van Eck, and T. J. van Berkel. 1997. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38: 1070-1084.
13. Jong, M. C., P. C. Rensen, V. E. Dahlmans, H. van der Boom, T. J. van Berkel, and L. M. Havekes. 2001. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid Res. 42: 1578-1585.
14. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Med. Sci. 37: 911-917.
15. Zechner, R. 1990. Rapid and simple isolation procedure for lipoprotein lipase from human milk. Biochim. Biophys. Acta. 1044: 20-25.
16. Rensen, P. C., M. C. Jong, L. C. van Vark, H. van der Boom, W. L. Hendriks, T. J. van Berkel, E. A. Biessen, and L. M. Havekes. 2000. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J. Biol. Chem. 275: 8564-8571.
17. Teusink, B., J. Voshol, V. E. Dahlmans, P. C. Rensen, H. Pijl, J. A. Romijn, and L. M. Havekes. 2003. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes. 52: 614-620.
18. Berbee, J. F., C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. Rensen. 2005. Severe hypertriglyceridemia in human APOCI transgenic mice is caused by apoC-I-induced inhibition of LPL. J. Lipid Res. 46: 297-306.
19. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
20. Aalto-Setälä, K., P. H. Weinstock, C. L. Bisgaier, L. Wu, J. D. Smith, and J. L. Breslow. 1996. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J. Lipid Res. 37: 1802-1811.
21. Coleman, T., R. L. Seip, J. M. Gimble, D. Lee, N. Maeda, and C. F. Semenkovich. 1995. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J. Biol. Chem. 270: 12518-12525.
22. Goudriaan, J. R., M. A. M. den Boer, P. C. N. Rensen, M. Febbraio, F. Kuipers, J. A. Romijn, L. M. Havekes, and P. J. Voshol. 2005. CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J. Lipid Res. 46: 2175-2181.
23. Clarke, A. R., and J. J. Holbrook. 1985. The mechanism of activation of lipoprotein lipase by apolipoprotein C-II. The formation of a protein-protein complex in free solution and at a triacylglycerol/water interface. Biochim. Biophys. Acta. 827: 358-368.
24. Shen, Y., A. Lookene, S. Nilsson, and G. Olivecrona. 2002. Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase. J. Biol. Chem. 277: 4334-4342.
25. Schaap, F. G., P. C. N. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. F. M. Chamuleau, L. M. Havekes, A. K. Groen and K. W. van Dȳk. 2004. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279: 27941-27947.
26. van der Hoogt, C. C., J. F. P. Berbee, S. M. S. Espirito Santo, G. Gerritsen, Y. D. Krom, A. van der Zee, L. M. Havekes, K. W. van Dȳk, and P. C. Rensen. 2006. Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice. Biochim. Biophys. Acta. 1761: 213-220.
27. Brown, W. V., and M. L. Baginsky. 1972. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem. Biophys. Res. Commun. 46: 375-382.
28. Havel, R. J., C. J. Fielding, T. Olivecrona, V. G. Shore, P. E. Fielding, and T. Egelrud. 1973. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources. Biochemistry. 12: 1828-1833.
29. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99: 2672-2681.
30. Huang, Y., X. Q. Liu, S. C. Rall, Jr., J. M. Taylor, A. von Eckardstein, G. Assmann, and R. W. Mahley. 1998. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273: 26388-26393.
31. Shimizugawa, T., M. Ono, M. Shimamura, K. Yoshida, Y. Ando, R. Koishi, K. Ueda, T. Inaba, H. Minekura, T. Kohama, et al. 2002. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 277: 33742-33748.
32. Yoshida, K., T. Shimizugawa, M. Ono, and H. Furukawa. 2002. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 43: 1770-1772.
33. Yu, X., S. C. Burgess, H. Ge, K. K. Wong, R. H. Nassem, D. J. Garry, A. D. Sherry, C. R. Malloy, J. P. Berger, and C. Li. 2005. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc. Natl. Acad. Sci. USA. 102: 1767-1772.
34. Ge, H., J-Y. Cha, H. Gopal, C. Harp, X. Yu, J. J. Repa, and C. Li. 2005. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J. Lipid Res. 46: 1484-1490.
35. Mandard, S., F. Zandbergen, E. van Straten, W. Wahli, F. Kuipers, M. Müller, and S. Kersten. 2006. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281: 934-944.
36. Prieur, X., H. Coste, and J. C. Rodriguez. 2003. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J. Biol. Chem. 278: 25468-25480.
37. Vu-Dac, N., P. Gervois, H. Jakel, M. Nowak, E. Bauge, H. Dehondt, B. Staels, L. A. Pennacchio, E. M. Rubin, J. Fruchart-Najib, et al. 2004. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J. Biol. Chem. 278: 17982-17985.
38. Kersten, S., S. Mandard, N. S. Tan, P. Escher, D. Metzger, P. Chambon, F. J. Gonzalez, B. Desvergne, and W. Wahli. 2000. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275: 28488-28493.
39. Yoshida, K., M. Ono, R. Koishi, and H. Furukawa. 2004. Characterization of the 5′ regulatory region of the mouse angiopoietin-like protein 4. Vet. Res. Commun. 28: 299-305.
40. Köster, A., Y. B. Chao, M. Mosior, A. Ford, P. A. Gonzalez-DeWhitt, J. E. Hale, D. Li, Y. Qiu, C. C. Fraser, D. D. Yang, et al. 2005. Transgenic angiopoietin-like (Angptl)4 overexpression and targeted disruption of Angptl4 and Angptl3: regulation of triglyceride metabolism. Endocrinology. 146: 4943-4950.
41. Goudriaan, J. R., P. J. Tacken, V. E. H. Dahlmans, M. J. J. Gijbels, K. W. van Dȳk, L. M. Havekes, and M. C. Jong. 2001. Protection from obesity in mice lacking the VLDL receptor. Arterioscler. Thromb. Vasc. Biol. 21: 1488-1493.
42. Goudriaan, J. R., S. M. S. Espirito Santo, P. J. Voshol, B. Teusink, K. W. van Dȳk, B. J. M. van Vlijmen, J. A. Romijn, L. M. Havekes, and P. C. N. Rensen. 2004. The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J. Lipid Res. 45: 1475-1481.